Studying Bone Marrow Immune Cells in Chronic Myelomonocytic Leukemia
Compares bone marrow macrophages in chronic myelomonocytic leukemia with those of healthy adults.
Plain-language title generated from the registry record
Registry title: Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia
Key facts
- Where
- Nice, FranceSee the site
Where in France
- CHU de NiceNice, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Trial code
- NCT07852494
- Record updated
- 1 October 2026
- Original description
MAC-AGE is a single-center study designed to characterize bone marrow macrophages in patients with chronic myelomonocytic leukemia (CMML) and to compare them with macrophages from age-matched controls undergoing elective total hip arthroplasty. Phenotypic, transcriptional and functional analyses will be performed using spectral/multiparametric flow cytometry, single-cell RNA sequencing and ex vivo functional assays. The study aims to identify CMML-associated macrophage alterations and potential therapeutic targets within the bone marrow immune microenvironment.Read full original descriptionShow less
Phenotypic and Functional Characterization of Bone Marrow Macrophages in Chronic Myelomonocytic Leukemia (CMML): Comparative Study With Age-Matched Healthy Controls
MAC-AGE is a single-center study designed to characterize bone marrow macrophages in patients with chronic myelomonocytic leukemia (CMML) and to compare them with macrophages from age-matched controls undergoing elective total hip arthroplasty. Phenotypic, transcriptional and functional analyses will be performed using spectral/multiparametric flow cytometry, single-cell RNA sequencing and ex vivo functional assays. The study aims to identify CMML-associated macrophage alterations and potential therapeutic targets within the bone marrow immune microenvironment.
Inclusion: Age ≥ 55 years; Confirmed diagnosis of chronic myelomonocytic leukaemia (CML) according to WHO criteria (2022 edition); Patient registered with or covered by a social security scheme; Bone marrow sample can be obtained during a scheduled consultation; Signed informed consent Exclusion criteria - Group 1; Active infection or acute inflammatory condition; Treatment with chemotherapy or immunosuppressants within the 4 weeks prior to the procedure; Medical contraindication to bone marrow aspiration; Person under guardianship, curatorship or legal protection; Secondary CMML; Age ≥ 55 years; Scheduled surgery for total hip replacement; No history of haematological malignancy or autoimmune disease; Signed informed consent; Patient registered with or covered by a social security scheme Exclusion criteria - Group 2; Active or uncontrolled chronic inflammatory condition; Autoimmune disease; Presence of a known haematological disorder, persistent monocytosis or an unexplained haematological abnormality; Chronic immunomodulatory or anti-inflammatory treatment; History of immunosuppression or chronic inflammatory disease; Persons under guardianship, curatorship or judicial protection.